While still a couple of years out, MD+DI gained some insights into Dexcom's next-generation sensor from an interview with the ...

Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook ...

DexCom, Inc. (NASDAQ:DXCM) is one of the Best Fundamental Stocks to Buy According to Analysts. On January 12, the company ...

In his inaugural J.P. Morgan Healthcare Conference speech, newly minted Dexcom CEO Jake Leach looked to ease concerns over ...

Dexcom’s new CEO is eyeing growth in the international market as a key strategy for 2026, fresh off the back of the company ...

DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...

Some of medtech's most innovative technologies were on display at the Consumer Electronics Show (CES) in Las Vegas this week.

Investing.com -- Barclays downgraded DexCom and Insulet, two large-cap diabetes device makers, to Underweight as it expects rising competition in 2026 and 2027 to weigh on valuation multiples and ...

There are exciting advancements in patient standard of care thanks to continuous health monitoring technologies.

V2X, Inc. is pleased to announce it has been awarded a contract under the Missile Defense Agency's (MDA) Scalable Homeland Innovative Enterprise Layered Defense (SHIELD) indefinite-delivery/indefinite ...

In July, Leach was tapped to take the CEO role permanently at the start of 2026 as part of Dexcom’s planned succession ...

Dexcom (NSDQ:DXCM) today announced preliminary fourth-quarter results that included revenues that topped the consensus ...